<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70637">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087241</url>
  </required_header>
  <id_info>
    <org_study_id>D6011C00002</org_study_id>
    <nct_id>NCT02087241</nct_id>
  </id_info>
  <brief_title>Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer</brief_title>
  <official_title>Double-Blind Randomised Phase II Trial of Carboplatin and Pemetrexed With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to combine AZD1775 with standard front-line chemotherapy in
      subjects with advanced NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, phase II trial comparing AZD1775
      plus carboplatin and pemetrexed with a maintenance phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the objective response rates in each arm</measure>
    <time_frame>Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The objective response rate is defined as the number of the subjects with a confirmed best overall response of CR or PR divided by the number of subjects in the Full Analysis Set (FAS) for whom measureable disease is present at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the disease control rate in each treatment arm</measure>
    <time_frame>Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>the disease control rate is defined as the percentage of FAS subjects with a best overall response of CR, PR or SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the duration of response in each treatment arm</measure>
    <time_frame>Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response is defined as the time from the date of first documented response until the date of documented progression or any cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety in each treatment arm</measure>
    <time_frame>Up to disease progression or unacceptable toxicity (there is no time limit on the length of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety profiles will be assessed in terms of AEs and laboratory data, vital signs, and ECG data that will be collected for all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess overall survival in each treatment arm</measure>
    <time_frame>Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the time from the date of randomization until death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>AZD1775+carboplatin and pemetrexed drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized - AZD1775 + carboplatin +pemetrexed Maintenance - AZD1775 + pemetrexed until disease progression or toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+carboplatin + pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized - Matching Placebo to AZD 1775 + carboplatin + pemetrexed, Maximum 4 Cycles Maintenance - AZD1775 + pemtrexed or  Matching Placebo AZD1775 + pemetrexed until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1775</intervention_name>
    <description>AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies</description>
    <arm_group_label>AZD1775+carboplatin and pemetrexed drug</arm_group_label>
    <other_name>MK-1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1775 Matching Placebo</intervention_name>
    <description>AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies</description>
    <arm_group_label>Placebo+carboplatin + pemetrexed</arm_group_label>
    <other_name>MK1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.</description>
    <arm_group_label>AZD1775+carboplatin and pemetrexed drug</arm_group_label>
    <arm_group_label>Placebo+carboplatin + pemetrexed</arm_group_label>
    <other_name>MK1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.</description>
    <arm_group_label>AZD1775+carboplatin and pemetrexed drug</arm_group_label>
    <arm_group_label>Placebo+carboplatin + pemetrexed</arm_group_label>
    <other_name>MK1775</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Provision of informed consent prior to any study specific procedures

          -  Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease
             (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).

          -  No prior chemotherapy for locally advanced or metastatic disease

          -  Subjects with a known EGFR mutation must have received previous treatment with an
             EGFR tyrosine kinase inhibitor; and subjects with a known ALK translocation must have
             received previous treatment with an ALK inhibitor.

          -  No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow
             area.

          -  At least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumours (RECIST) v1.1

          -  Mandatory availability of tumour tissue (archival or fresh if archival is not
             available) for TP53 determination.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.

          -  Absolute neutrophil count (ANC) ≥1500/μL

          -  Hemoglobin (Hgb) ≥10 g/dL

          -  Platelets ≥100,000/μL

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ≤3.0 x the upper
             limit of normal (ULN); 5 x ULN if known hepatic metastases

          -  Total bilirubin ≤1.5 x ULN, unless secondary to Gilbert's disease

          -  Serum creatinine ≤1.5 x ULN and a calculate creatinine clearance (CrCl) ≥45 mL/min by
             the Cockcroft-Gault method

          -  Ability to swallow oral medication

          -  Fertile male subjects willing to use at least one medically acceptable form of birth
             control for the duration of the study and for 2 weeks after treatment stops

          -  Female subjects who are not of childbearing potential and fertile female subjects of
             childbearing potential who agree to use adequate contraceptive measures who are not
             breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours
             prior to start of study treatment

          -  Predicted life expectancy ≥12 weeks

          -  Must be ≥18 years of age

          -  Willingness and ability to comply with study and follow-up procedures

          -  Ability to understand the nature of this trial and give written informed consent
             Exclusion criteria

          -  Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the
             first dose of AZD1775

          -  Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures
             ≤7 days

          -  Known central nervous system (CNS) disease

          -  Subject has had prescription or non-prescription drugs or other products (i.e.
             grapefruit juice) known to be sensitive CYP3A4 substrates

          -  Any known hypersensitivity or contraindication to the components of study treatment

          -  Any of the following cardiac diseases currently or within the last 6 months as
             defined by New York Heart Association ([NYHA] Appendix G) ≥ Class 2

          -  Corrected QT interval (QTc) &gt;470 msec (as calculated by Fridericia correction
             formula) at study entry or congenital long QT syndrome.

          -  Pregnant or lactating

          -  Any serious, active underlying medical condition that would impair the ability of the
             subjects to receive study treatment

          -  Unable or unwilling to take folic acid or vitamin B12

          -  Presence of other active cancers, or history of treatment for invasive cancer ≤3
             years

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Spigel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernadette M Weidman</last_name>
    <phone>302-897-5559</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanne Meredith</last_name>
    <phone>(813) 920-7423</phone>
    <email>joanne.meredith@astrazeneca.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IV Lung Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
